Cost‐effectiveness analysis of low‐dose direct oral anticoagulant (DOAC) for the prevention of cancer‐associated thrombosis in the United States-Reference-Cited by-同舟云学术

Cost‐effectiveness analysis of low‐dose direct oral anticoagulant (DOAC) for the prevention of cancer‐associated thrombosis in the United States

Published:2020-04-15 Issue:8 Volume:126 Page:1736-1748
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Li Ang¹^ORCID,Carlson Josh J.²^ORCID,Kuderer Nicole M.³,Schaefer Jordan K.⁴^ORCID,Li Shan⁵,Garcia David A.¹,Khorana Alok A.⁶,Carrier Marc⁷,Lyman Gary H.⁸⁹

Affiliation:

1. Division of Hematology University of Washington School of Medicine Seattle Washington

2. The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute University of Washington School of Pharmacy Seattle Washington

3. Advanced Cancer Research Group and Department of Medicine University of Washington Seattle Washington

4. Division of Hematology/Oncology, Department of Internal Medicine University of Michigan Ann Arbor Michigan

5. Pharmacy Services University of Washington Medical Center Seattle Washington

6. Department of Hematology and Medical Oncology Taussig Cancer Institute and Case Comprehensive Cancer Center Cleveland Clinic Cleveland Ohio

7. Department of Medicine Ottawa Hospital Research Institute University of Ottawa Ottawa Ontario Canada

8. Division of Medical Oncology University of Washington School of Medicine Seattle Washington

9. Public Health Sciences Division Fred Hutchinson Cancer Research Center Seattle Washington

Funder

Cleveland Clinic

Hemostasis and Thrombosis Research Society

Conquer Cancer Foundation

National Hemophilia Foundation

University of Ottawa

National Heart, Lung, and Blood Institute

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32724

Reference44 articles.

1. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy

2. Prognosis of Cancers Associated with Venous Thromboembolism

3. Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States

4. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis

5. Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting VTE and utility of thromboprophylaxis in metastatic and recurrent cervical cancer;Gynecologic Oncology;2024-09

2. Preventative and curative treatment of venous thromboembolic disease in cancer patients;La Presse Médicale;2024-09

3. DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism;Nature Medicine;2024-08-15

4. ‘X’ marks the spot! Utilising factor Xa inhibitors to optimise thromboprophylaxis in multiple myeloma;British Journal of Haematology;2024-07-10

5. Improvement of thrombosis management in patients with cancer: a practical consensus document of recommendations for cancer-associated thrombosis patients’ healthcare in Spain;Clinical and Translational Oncology;2024-02-13